The combination of molecular biology, engineering and bioinformatics has revolutionized our understanding of cancer revealing a tight correlation of the molecular characteristics of the primary tumor in terms of gene expression, structural alterations of the genome, epigenetics and mutations with its propensity to metastasize and to respond to therapy. It is not just one or a few genes, it is the complex alteration of the genome that determines cancer development and progression. Future management of cancer patients will therefore rely on thorough molecular analyses of each single case. Through this book, students, researchers and oncologists will obtain a comprehensive picture of what the first ten years of cancer genomics have revealed. Experts in the field describe, cancer by cancer, the progress made and its implications for diagnosis, prognosis and treatment of cancer. The deep impact on the clinics and the challenge for future translational research become evident.
Assembled in an accessible format specifically designed for the non-expert, this book provides the clinical oncologist, early career practitioner, and trainee with an essential understanding of the molecular and genetic basis of cancer and ...
Tools such as sidebars, key concept summaries, a glossary, and acronym and abbreviation definitions make this book highly accessible to researchers from several fields associated with cancer genomics.
Potts MB, Cameron S. Cell lineage and cell death: Caenorhabditis elegans and cancer research. Nat Rev Cancer. 2011;11:50–58. Rudrapatna VA, Cagan RL, Das TK. Drosophila cancer models. Dev Dyn. 2012;241:107–118.
The vast amount of genomic data being produced by the research community is becoming readily accessible to biomedical researchers and clinicians to apply to their cancer(s) of interest.
The number of people diagnosed with cancer each year will almost double to 21 million cases worldwide by 2030 because of the aging population.
In the light of a rapidly evolving field of breast cancer genomics, this chapter highlights key standard and upcoming approaches for diagnosis, prognosis and treatment and discusses the feasibility of genome-oriented personalized treatments ...
The book concludes with a chapter on the limitations and cost-effectiveness of NGS in CRC. Given its scope, the book will appeal to all those interested in learning about the potential of NGS in advancing CRC research and patient care.
Penney KL, Sinnott JA, Fall K, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011;29:2391–2396. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes.
We describe past, current and upcoming sequencing technologies and the application of second-generation sequencing technologies in cancer genomics.
The discovery of microRNA (miRNA) involvement in cancer a decade ago, and the more recent findings of long non-coding RNAs in human diseases, challenged the long-standing view that RNAs without protein-coding potential are simply “junk” ...